TLDRocket
Sign in

Qureight secures $20M Series B to expand AI-powered imaging platform for clinical trials

Tech.eu Cate Lawrence

Qureight, an AI imaging company for clinical trials, raised $20 million in Series B funding led by Molten Ventures to expand its platform. The company will use the capital to develop new disease models in asthma, pulmonary hypertension, bronchiectasis, and drug-induced lung toxicity, complementing existing lung fibrosis models. This enables Qureight to enter new markets and strengthen its position as a clinical trials imaging provider across more disease areas.

Why it matters

Qureight, an end-to-end imaging company that provides enterprise-grade imaging and precision endpoints for clinical trials with a focus on lung and heart disease, today announced it has raised $20 mil...

Related stories

The daily briefing

Every AI story that matters, in your inbox by 8am.

TLDRocket reads 60+ sources, removes duplicate coverage, and summarises the day in two minutes. Free, no spam, unsubscribe anytime.